Tag Archives: Certain

Increase of Certain Fatty Acids Can Help Reduce Migraine Severity

Migraine is among the biggest reasons for disability worldwide. Current treatment options are sometimes inadequate for providing complete relief for sufferers. Research has found that a change in diet provides one more option sufferers are able to use in their attempt to have less headaches and migraines.1✅ JOURNAL REFERENCEDOI: 10.1136/bmj.n1448 Polyunsaturated fatty acids, which the… Read More »

HHS to allow for the importation of certain drugs from Canada and other countries in an attempt to lower costs

The Department of Health and Human Services on Friday announced that the Trump Administration will move forward with drug importations from other countries, promising to pass discounts onto consumers in an effort to follow through on the president’s executive order on drug pricing. HHS Chief of Staff Brian Harrison said this marks the first time… Read More »

Hispanics in Certain Counties More Likely to Die from Heart Disease, Stroke

(Juanmonino/Getty Images) Hispanic adults who live in counties with high concentrations of their ethnic peers are about 60 percent more likely than those who don’t to die from heart disease and stroke, a new study shows. As a group, Hispanics have lower death rates from heart disease and stroke than white and black adults –… Read More »

FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

Print this page KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.– September 17, 2019 — (BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima, the orally available kinase inhibitor discovered by… Read More »

FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers

FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers Print this page South San Francisco, CA — February 28, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous (under… Read More »

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »